## SEC Form 4

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

		son <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC</u> [FOLD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u> <del>- <u> </u></del></u>	<u></u>				Director	10% Owner			
				х	Officer (give title	Other (specify			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	below)			
C/O AMICUS THERAPEUTICS, INC.		S, INC.	12/04/2014	Chairman & CEO					
1 CEDAR BRO	OK DRIVE								
,			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filing	(Check Applicable			
(Street)				Line)					
CRANBURY	NJ	08512		X	Form filed by One Repo	orting Person			
					Form filed by More thar Person	One Reporting			
(City)	(State)	(Zip)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	12/04/2014		P <sup>(1)</sup>		89,000	A	<b>\$8.3585</b> <sup>(2)</sup>	198,083	D	
Common Stock	12/04/2014		<b>S</b> <sup>(1)</sup>		89,000	D	<b>\$8.3585</b> <sup>(3)</sup>	109,083	D	
Common Stock								64,895	I	By Trust

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$5.325	12/04/2014		M <sup>(1)</sup>			89,000	10/01/2009	10/20/2015	Common Stock	89,000	\$0.00	0	D	

#### Explanation of Responses:

1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2014.

2. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$8.35 to \$8.40. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. 3. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$8.35 to \$8.40. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

#### Remarks:

The stock options exercised under this Rule 10b5-1 trading plan were due to expire on October 20, 2015. After this transaction, Mr. Crowley holds stock options for 2.1 million shares of Amicus Therapeutics, Inc. common stock.

/s/ John F. Crowley

\*\* Signature of Reporting Person

12/08/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.